4.2. Diagnostic Evaluations for nAMD and Exclusion Criteria

The hospital’s electronic patient database was used to search for the nAMD patients treated with intravitreal anti-VEGF agents by using the ICD-10 (International Classification of Diseases) diagnosis code for nAMD (H35.31). All patients with a nAMD diagnosis had undergone a comprehensive ophthalmic examination, evaluation of best-corrected visual acuity, and fundus imaging (fundus photography, fluorescein angiogram, optical coherence tomography (OCT), and optical coherence tomography angiography (OCT-A)) based on the discretion of the treating physician and the availability of the imaging techniques during the follow-up period. The cases of dry AMD, polypoidal choroidal vasculopathy (PCV), myopic degeneration, or other retinal disorders, such as diabetic macular edema, treated with anti-VEGF injections were excluded from the study. Patients with less than three consecutive anti-VEGF injections, a follow-up time less than 3 months, or a diagnosis of dry AMD were excluded from the study.